Bar-Ad Voichita, Mishra Mark, Ohri Nitin, Intenzo Charles
Department of Radiation Oncology, Thomas Jefferson University, 111 S. 11th Street, Philadelphia, PA 19107, USA.
Rev Recent Clin Trials. 2012 Feb;7(1):36-41. doi: 10.2174/157488712799363226.
The objective of the current review was to assess published data on the role of Positron Emission Tomography (PET) for evaluation of nodal residual disease after definitive chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).
Studies were identified by searching PubMed electronic databases. Only studies using a post-chemoradiotherapy PET for nodal residual disease evaluation were included in the present review. Both prospective and retrospective studies were included. Information regarding sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET for detecting nodal residual disease after definitive chemoradiotherapy for HNSCC was extracted and analyzed.
Twenty published studies were included in the present review. Existing data suggest that a negative post-chemoradiotherapy PET scan is associated with a negative predictive value up to 100%. The sensitivity of PET in detecting nodal residual disease is greater for scans performed ≥ 10 weeks after definitive treatment with chemoradiotherapy for HNSCC.
Further studies are needed to quantify the reliability of PET in detecting nodal residual disease after chemoradiotherapy for locoregionally advanced HNSCC. The optimal timing of PET imaging after chemoradiotherapy remains to be defined.
本综述的目的是评估已发表的数据，以探讨正电子发射断层扫描（PET）在评估头颈部鳞状细胞癌（HNSCC）根治性放化疗后淋巴结残留疾病中的作用。
通过检索PubMed电子数据库来识别研究。本综述仅纳入使用放化疗后PET评估淋巴结残留疾病的研究。前瞻性和回顾性研究均包括在内。提取并分析了关于PET检测HNSCC根治性放化疗后淋巴结残留疾病的敏感性、特异性、阳性预测值、阴性预测值和准确性的信息。
本综述纳入了20项已发表的研究。现有数据表明，放化疗后PET扫描结果为阴性与高达100%的阴性预测值相关。对于HNSCC根治性放化疗后≥10周进行的扫描，PET检测淋巴结残留疾病的敏感性更高。
需要进一步研究以量化PET在检测局部晚期HNSCC放化疗后淋巴结残留疾病中的可靠性。放化疗后PET成像的最佳时机仍有待确定。
